Ezetimibe-atorvastatin SPC approved in China; economic value assessment needed
The single-pill combination of ezetimibe and atorvastatin was approved in China in 2023 and added to the NRDL in 2024.
Asset / Drug
Drug and asset intelligence for Ezetimibe with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.